1004618-85-2 Usage
Uses
Used in Pharmaceutical Research:
4-(4-(TrifluoroMethoxy)phenyl)piperidine hydrochloride is used as a research compound for its potential as a serotonin reuptake inhibitor, which is a key mechanism in the treatment of various neurological and psychiatric disorders.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-(4-(TrifluoroMethoxy)phenyl)piperidine hydrochloride is used as a starting material or intermediate in the synthesis of new drugs targeting neurological and psychiatric conditions.
Used in Laboratory Research:
4-(4-(TrifluoroMethoxy)phenyl)piperidine hydrochloride is used in laboratory research to study its analgesic and anti-inflammatory properties, which could potentially lead to the development of new pain relief and anti-inflammatory medications.
Used in the Development of Neurological and Psychiatric Treatments:
4-(4-(TrifluoroMethoxy)phenyl)piperidine hydrochloride is used as a potential therapeutic agent in the development of treatments for neurological and psychiatric disorders, given its potential as a serotonin reuptake inhibitor.
Note: 4-(4-(TrifluoroMethoxy)phenyl)piperidine hydrochloride is not approved for clinical use in humans and is currently limited to research and development purposes.
Check Digit Verification of cas no
The CAS Registry Mumber 1004618-85-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,4,6,1 and 8 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1004618-85:
(9*1)+(8*0)+(7*0)+(6*4)+(5*6)+(4*1)+(3*8)+(2*8)+(1*5)=112
112 % 10 = 2
So 1004618-85-2 is a valid CAS Registry Number.
1004618-85-2Relevant academic research and scientific papers
(6,7-DIHYDRO-2-NITRO-5H-IMIDAZOL[2,1-B][1,3]OXAZIN-6-YL) AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF
-
Paragraph 0075-0076, (2013/04/10)
(6,7-Dihydro-2-nitro-5H-imidazo [2,1-b][1,3]oxazin-6-yl)amide compounds of formula (I), and their pharmaceutically acceptable salts, preparation methods and pharmaceutical compositions thereof are disclosed, wherein m and R are defined as in the descripti
AZABENZIMIDAZOLYL COMPOUNDS
-
Page/Page column 62, (2008/06/13)
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR
-
Page/Page column 65-66, (2010/11/30)
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
